HLA B57:01 Molecular Detection
Test Catalog Information
| Test Catalog Synonyms | |
| EPIC Synonyms |
Abacavir Sensitivity HLAB5701 HLA-B 5701 Genotype HLA Antigen B5701 Abacavir hypersensitivity genotyping |
| Cerner Primary Mnemonic | HLX HLA Antigen B5701 Case |
| EPIC Display Name | HLA B57:01 Molecular Detection |
| Allscripts (AEHR) Order Name | HLX HLA B57-01 Antigen Case |
| Sunrise Clinical Manager (SCM) Order Name | HLX HLA B57-01 Antigen Case |
| EPIC Inpatient Orderable | Yes |
| EPIC Outpatient Orderable | Yes |
| Cerner Results | |
| Clinical Info |
Hypersensitivity to abacavir has been strongly associated with the HLA-B*57:01 allele. DNA-based testing to assess the presence of HLA-B*57:01 offers higher specificity than serologic testing because monoclonal antibodies may show cross-reactivity with other HLA subtypes. The U.S. Food and Drug Administration (FDA) recommends pre-therapeutic screening for the HLA-B*57:01 allele. Routine screening has been shown to reduce the incidence of ABC HSR from 8% to <0.5% in abacavir-naïve patients. Patients testing positive should not be treated with a regimen containing abacavir. |
| Specimen Type |
Blood |
| Container |
Lavender Top Tube |
| Collection Instructions |
Container/Tube: Lavender Top (EDTA) tube Specimen: 1-3 mL of peripheral blood Specimens should be accompanied by a test request form and a signed consent form stating that the patient agrees to be tested for HLA-B*5701 genotyping. The consent form should be signed by the patient or designee and the health care provider. |
| Transport Instructions |
Room Temperature |
| Specimen Stability |
Specimens are stable for a week refrigerated. |
| Methodology |
Real Time Polymerase Chain Reaction (RT-PCR) |
| Days Performed |
Monday through Friday TAT: 8 Calendar days |
| Performing Laboratory |
Northwell Health Laboratories |
| CPT |
81381 |
| PDM |
228468 |
Desired Epic Build HLA B57:01 Molecular Detection
| Cerner Primary Mnemonic: | HLX HLA Antigen B5701 Case |
| PDM | 228468 |
| Informatics - Workgroup | Molpath inhouse |
| Synonyms * | Abacavir Sensitivity HLAB5701 HLA-B 5701 Genotype HLA Antigen B5701 Abacavir hypersensitivity genotyping |
| Display Name * | HLA B57:01 Molecular Detection |
| Order Entry Specimen Sources * | |
| Order Entry Specimen Types |
Blood
|
| Specimen Navigator Specimen Types | |
| Specimen Navigator Specimen Sources | |
| Specimen Navigator Short Name | |
| Ordering info (EPIC SmartText) | Hypersensitivity to abacavir has been strongly associated with the HLA-B*57:01 allele. DNA-based testing to assess the presence of HLA-B*57:01 offers higher specificity than serologic testing because monoclonal antibodies may show cross-reactivity with other HLA subtypes. The U.S. Food and Drug Administration (FDA) recommends pre-therapeutic screening for the HLA-B*57:01 allele. Routine screening has been shown to reduce the incidence of ABC HSR from 8% to <0.5% in abacavir-naïve patients. Patients testing positive should not be treated with a regimen containing abacavir. |
| IP Orderable | Yes |
| OP Orderable | Yes |
|
AOEs * | |
| AP AOEs | |
| Special History | No |
| Build Comments | |
| Filter * | genetics |
| Procedure Category Change | |
| Cerner Results | |
Actual Epic build
| Procedure Id | 115147 | ||||||||||||
| Pdm | 228468 | ||||||||||||
| Order Display Name | HLA B57:01 Molecular Detection | ||||||||||||
| Procedure Name | HLX HLA B57-1 ANTIGEN CASE | ||||||||||||
| Procedure Master Number | LAB11403 | ||||||||||||
| Short Procedure Name | HLX HLA B57-1 ANTIGEN CASE | ||||||||||||
| Category Code | 21.0 | ||||||||||||
| Category Code Record Name | LAB MOLECULAR DIAGNOSTICS ORDERABLES | ||||||||||||
| Synonyms | ABACAVIR SENSITIVITY HLAB5701 HLA-B 5701 GENOTYPE HLA ANTIGEN B5701 ABACAVIR HYPERSENSITIVITY GENOTYPING | ||||||||||||
| Clinically Active | Yes | ||||||||||||
| Orderable | Yes | ||||||||||||
| Performable | Yes | ||||||||||||
| Filter Genomics | Generic Genomics Procedure | ||||||||||||
| Reference Link Url | https://labs.northwell.edu/epic/test/115147 | ||||||||||||
| Ordering Instructions | Hypersensitivity to abacavir has been strongly associated with the HLA-B*57:01 allele. DNA-based testing to assess the presence of HLA-B*57:01 offers higher specificity than serologic testing because monoclonal antibodies may show cross-reactivity with other HLA subtypes. The U.S. Food and Drug Administration (FDA) recommends pre-therapeutic screening for the HLA-B*57:01 allele. Routine screening has been shown to reduce the incidence of ABC HSR from 8% to <0.5% in abacavir-navØve patients. Patients testing positive should not be treated with a regimen containing abacavir. | ||||||||||||
| Default Specimen Type | Blood | ||||||||||||
| Specimen Type Pick List | Blood | ||||||||||||
| Specimen Type List | |||||||||||||
| Op Specimen Type List | |||||||||||||
| Specimen Source Pick List | Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous | ||||||||||||
| Specimen Source Default - Male | |||||||||||||
| Specimen Source Default - Female | |||||||||||||
| Specimen Source List | |||||||||||||
| Op Specimen Source List | |||||||||||||
| Ip Lab Test Components For Report | HLXB57501 | ||||||||||||
| Op Lab Test Components For Report | HLXB57501 | ||||||||||||
| Order Questions | ["3048500000"] | ||||||||||||
| Order Questions Record Name | |||||||||||||
| Inpatient Order Questions | ["3048500000"] | ||||||||||||
| Inpatient Order Questions Record Name | |||||||||||||
| Order Specific Question Override | |||||||||||||
| Inpatient Question Override | |||||||||||||
| Location Restrict List Ip | |||||||||||||
| Location Restrict List Ip Record Name | |||||||||||||
| Location Restrict List Include Ip | |||||||||||||
| Location Restrict List Op | |||||||||||||
| Location Restrict List Op Record Name | |||||||||||||
| Location Restrict List Includes Op | |||||||||||||
| Edp Amb Order Specific Questions Record Name | NH IP PATIENT COMPLETED CONSENT | ||||||||||||
| Edp Ip Order Specific Questions Record Name | NH IP PATIENT COMPLETED CONSENT | ||||||||||||
| Edp Ip Specimen Source | |||||||||||||
| Edp Op Specimen Source | |||||||||||||
| Edp Ip Specimen Type | |||||||||||||
| Edp Op Specimen Type | |||||||||||||
| Derived Edp Ip Buttons S | |||||||||||||
| Derived Edp Ip Buttons T | |||||||||||||
| Derived Edp Op Buttons S | |||||||||||||
| Derived Edp Op Buttons T | |||||||||||||
| Ip Orderable | 1 | ||||||||||||
| Op Orderable | 1 | ||||||||||||
EPIC OP AOEs
| |||||||||||||
EPIC IP AOEs
| |||||||||||||
| EPIC Components (results) | |||||||||||||